{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:16:23Z","timestamp":1763442983619,"version":"3.45.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Mixed-phenotype acute leukemia (MPAL) is a rare subtype of acute leukemia with unfavorable outcome. There is no established optimal therapy regime.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis in our transplant center to clarify the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of MPAL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study monitored 61 MPAL patients who underwent allo-HSCT at a single center in China. Haploidentical donor HSCT was 41, matched unrelated donor HSCT was 4, and matched sibling donor HSCT was 16. The median age at diagnosis was 32 years (range, 14-58). The two most common phenotypes were B-lymphoid\/myeloid (n=33, 54.1%) and T-lymphoid\/myeloid (n=22, 36.1%). In induction treatment, 50 (82.0%) patients received an ALL-like treatment protocol, and 15 of the 17 BCR::ABL1 positive patients received tyrosine kinase inhibitor (TKI) therapy. After induction treatment, 38 (62.3%) patients achieved complete remission (CR). Pre-HSCT 55\/61 (90.2%) acquired complete remission (CR) and 46\/61 (75.4%) turned minimal residual disease (MRD) -negative. The median follow up time was 28.2 months. The estimated 2-year overall survival (OS) rates after HSCT were 80.0% \u00b1 6.0%. And the relapse-free survival (RFS) probabilities at 2-year were 68.0\u00b17.0%. There was no significant difference in OS and RFS among different types of HSCT. Patients with MRD-positive pre-HSCT was associated with worse OS (P=0.022). Patients who achieved CR after induction therapy had a longer RFS (P=0.033).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Allo-HSCT is effective in the treatment of MPAL especially in patients who achieved CR after induction therapy or who got MRD-negative pre-HSCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1691762","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:12:49Z","timestamp":1763442769000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic hematopoietic stem cell transplantation for mixed-phenotype acute leukemia: a single-center study"],"prefix":"10.3389","volume":"16","author":[{"given":"Mengze","family":"Hao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihua","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.202","article-title":"Mixed-phenotype acute leukemia: historical overview and a new definition","volume":"24","author":"Weinberg","year":"2010","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2021.03.016","article-title":"Update on acute leukemias of ambiguous lineage","volume":"41","author":"Aggarwal","year":"2021","journal-title":"Clin Lab Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.path.2019.03.008","article-title":"Acute leukemias of ambiguous lineage: clarification on lineage specificity","volume":"12","author":"Kurzer","year":"2019","journal-title":"Surg Pathol Clin"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0058-4","article-title":"Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis","volume":"32","author":"Maruffi","year":"2018","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.174441","article-title":"Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT","volume":"102","author":"Munker","year":"2017","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.02.013","article-title":"Allogeneic hematopoietic cell transplantation for patients with mixed phenotype acute leukemia","volume":"22","author":"Munker","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B8","doi-asserted-by":"publisher","first-page":"107309","DOI":"10.1016\/j.leukres.2023.107309","article-title":"Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group","volume":"130","author":"Kirtek","year":"2023","journal-title":"Leuk Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11912-020-01010-w","article-title":"Mixed phenotype acute leukemia: current approaches to diagnosis and treatment","volume":"23","author":"Alexander","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/s41409-024-02266-7","article-title":"Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients","volume":"59","author":"Zhang","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2023.04.002","article-title":"Chinese consensus on minimal residual disease detection and interpretation of patients with acute lymphoblastic leukemia (2023)","volume":"44","author":"Sun","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn121090-20240608-00214","article-title":"Chinese expert consensus on the diagnosis and treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation (2024)","volume":"45","author":"Sun","year":"2024","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05162-0","article-title":"Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study","volume":"102","author":"Lazzarotto","year":"2023","journal-title":"Ann Hematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s12308-023-00535-w","article-title":"Mixed-phenotype acute leukemia, T\/megakaryoblastic: does it really exist","volume":"16","author":"Mansoor","year":"2023","journal-title":"J Hematop"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25771","article-title":"Diagnostic workup of acute leukemias of ambiguous lineage","volume":"95","author":"Patel","year":"2020","journal-title":"Am J Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0436-0","article-title":"The genetic basis and cell of origin of mixed phenotype acute leukaemia","volume":"562","author":"Alexander","year":"2018","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1038\/s41467-018-04924-z","article-title":"Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes","volume":"9","author":"Takahashi","year":"2018","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.704471","article-title":"PHF6 mutations in hematologic Malignancies","volume":"11","author":"Kurzer","year":"2021","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000322","article-title":"Mixed-phenotype acute leukemia: current challenges in\u00a0diagnosis and therapy","volume":"24","author":"Wolach","year":"2017","journal-title":"Curr Opin Hematol"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-188461","article-title":"Treatment outcomes for adults with mixed phenotypic acute leukemia: A large single-Center retrospective study","author":"Huang","year":"2023"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.6517","article-title":"Hematopoietic stem cell transplant for adults with mixed phenotypic acute\u00a0leukemia","author":"Huang","year":"2024"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact\u00a0of\u00a0pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01252-w","article-title":"Mixed phenotype\/lineage leukemia: has anything changed\u00a0for 2021 on diagnosis, classification, and treatment","volume":"24","author":"B\u00e9n\u00e9","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12185-023-03614-x","article-title":"Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy","volume":"118","author":"Al-Shaibani","year":"2023","journal-title":"Int J Hematol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-020-01017-7","article-title":"Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Xuan","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02141-x","article-title":"Unmanipulated haploidentical hematopoietic stem cell transplantation for mixed phenotype acute leukemia: a single center study","volume":"59","author":"Huang","year":"2024","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1691762\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:12:51Z","timestamp":1763442771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1691762\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1691762"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1691762","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"article-number":"1691762"}}